A randomized, open-label, multicenter, parallel group treatment, phase 3, two-arm study to measure the effect on overall survival and quality of life of immediate curative therapy compared with standard conservative treatment in older male participants aged ≥ 75 years with non-metastatic, high-risk prostate cancer
Recruiting now
It is currently unclear if immediate curative treatment (radiotherapy or surgery) of high-risk prostate cancer without metastasis in older men (\>=75 years) generates the same survival benefits as in younger patients or if the harms/ side-effects of immediate curative treatment o…
Phase 3 • Sponsor: Sven Löffeler
Last updated Sep 10, 2026 16:00 UTC